IFG Advisory’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-17,738
| Closed | -$870K | – | 556 |
|
|
2025
Q4 | $870K | Sell |
17,738
-893
| -5% | -$41.6K | 0.04% | 399 |
|
|
2025
Q3 | $804K | Sell |
18,631
-77
| -0.4% | -$3.01K | 0.04% | 399 |
|
|
2025
Q2 | $718K | Buy |
18,708
+991
| +6% | +$37.9K | 0.04% | 408 |
|
|
2025
Q1 | $686K | Buy |
17,717
+1,624
| +10% | +$59.5K | 0.04% | 377 |
|
|
2024
Q4 | $544K | Sell |
16,093
-176
| -1% | -$6.34K | 0.03% | 401 |
|
|
2024
Q3 | $665K | Buy |
16,269
+1,664
| +11% | +$68.1K | 0.04% | 311 |
|
|
2024
Q2 | $562K | Buy |
14,605
+1,638
| +13% | +$68.9K | 0.04% | 379 |
|
|
2024
Q1 | $556K | Sell |
12,967
-1,368
| -10% | -$56.4K | 0.04% | 305 |
|
|
2023
Q4 | $531K | Sell |
14,335
-2,637
| -16% | -$94.7K | 0.04% | 356 |
|
|
2023
Q3 | $615K | Sell |
16,972
-2,452
| -13% | -$87K | 0.05% | 307 |
|
|
2023
Q2 | $692K | Buy |
19,424
+1,561
| +9% | +$56K | 0.06% | 246 |
|
|
2023
Q1 | $636K | Sell |
17,863
-3,580
| -17% | -$125K | 0.06% | 273 |
|
|
2022
Q4 | $753K | Sell |
21,443
-82
| -0.4% | -$2.73K | 0.08% | 244 |
|
|
2022
Q3 | $633K | Buy |
21,525
+10,111
| +89% | +$383K | 0.06% | 280 |
|
|
2022
Q2 | $621K | Sell |
11,414
-12,793
| -53% | -$706K | 0.07% | 260 |
|
|
2022
Q1 | $1.32M | Sell |
24,207
-1,047
| -4% | -$56.9K | 0.13% | 175 |
|
|
2021
Q4 | $1.39M | Buy |
25,254
+721
| +3% | +$37.5K | 0.14% | 171 |
|
|
2021
Q3 | $1.17M | Buy |
24,533
+5,345
| +28% | +$268K | 0.13% | 183 |
|
|
2021
Q2 | $955K | Buy |
19,188
+13,402
| +232% | +$644K | 0.11% | 202 |
|
|
2021
Q1 | $258K | Buy |
5,786
+285
| +5% | +$12.9K | 0.03% | 419 |
|
|
2020
Q4 | $253K | Buy |
5,501
+1,090
| +25% | +$50.1K | 0.04% | 385 |
|
|
2020
Q3 | $207K | Sell |
4,411
-510
| -10% | -$25.6K | 0.03% | 393 |
|
|
2020
Q2 | $250K | Buy |
4,921
+9
| +0.2% | +$462 | 0.05% | 338 |
|
|
2020
Q1 | $232K | Sell |
4,912
-373
| -7% | -$19.9K | 0.05% | 316 |
|
|
2019
Q4 | $310K | Buy |
5,285
+1,107
| +26% | +$61.6K | 0.06% | 308 |
|
|
2019
Q3 | $222K | Sell |
4,178
-3,649
| -47% | -$188K | 0.04% | 367 |
|
|
2019
Q2 | $391K | Sell |
7,827
-3,514
| -31% | -$176K | 0.07% | 231 |
|
|
2019
Q1 | $592K | Buy |
11,341
+338
| +3% | +$16.9K | 0.11% | 177 |
|
|
2018
Q4 | $525K | Sell |
11,003
-636
| -5% | -$31.3K | 0.12% | 171 |
|
|
2018
Q3 | $584K | Buy |
11,639
+18
| +0.2% | +$915 | 0.11% | 183 |
|
|
2018
Q2 | $585K | Sell |
11,621
-225
| -2% | -$11.3K | 0.12% | 161 |
|
|
2018
Q1 | $578K | Sell |
11,846
-1,656
| -12% | -$77.1K | 0.13% | 164 |
|
|
2017
Q4 | $598K | Buy |
+13,502
| New | +$624K | 0.13% | 154 |
|
Other funds holding GSK
JEST
IFG Advisory's GSK Position: Q1 2026 in Review
IFG Advisory sold out of GSK (GSK) in Q1 2026, closing a stake of 17,738 shares — an estimated $870K sold.
IFG Advisory first reported a position in GSK in Q4 2017 and held it in 33 quarters. The position peaked at $1.39M in Q4 2021. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- IFG Advisory reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
- IFG Advisory sold 17,738 GSK shares in Q1 2026, an estimated $870K.
- IFG Advisory first reported a position in GSK in Q4 2017 and held it in 33 quarters.
- IFG Advisory's GSK position peaked at $1.39M in Q4 2021.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on IFG Advisory's 13F filing for Q1 2026, filed 12 May 2026.